PRQR logo

PROQR THERAPEUTICS NV

PRQRNASDAQ
🏆 #3799 by market capUS Equity
$863.53▲ $50.60 (+5.86%)
Simulated price
🔔
Track PRQR
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 5.9%
7d—
14d—
30d—
ytd—
1y—
🏦Market Cap
$179M
Small Cap
📈Revenue Growth (YoY)
-19.2%
Declining
📊Gross Margin
92.3%
High
💵FCF Margin
-270.8%
Thin
⚖️P/S Ratio
8.5x
Elevated
Otter Score
56
Weak
No chart data available for PRQR.

Trading Snapshot

Day Range
$858.48 – $868.06
52-Week Range
$1.33 – $3.10
Volume
$3.57B
Avg Volume
$4.50B
Shares Outstanding
105.3M
Next Earnings
Nov 4, 2026

Fundamentals Snapshot

Annual Revenue
$15M
Last Q Revenue
$9M
P/E Ratio
-3.8
P/S Ratio
8.5x
EPS (TTM)
$-0.39
Dividend Yield
0.00%
Dilution (1yr)
+26.1%

Why Investors Own PRQR

  • ✓High-growth profile — revenue up +54.9% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 38% gross margin and 18% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

PRQR logo

PROQR THERAPEUTICS NV

PRQR
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$15M▼ −19.2% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
83.0%▼ −17.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$42M▲ +38.3% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$54M▲ +42.3% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
103.0M▲ +26.1% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$92M▼ −$47M YoY
StockOtter · stockotter.space

About PROQR THERAPEUTICS NV

ProQR Therapeutics N.V. operates as a biopharmaceutical enterprise dedicated to discovering and developing RNA-based therapies designed to address genetic disorders. The company's pipeline includes two primary drug candidates in advanced clinical stages: Sepofarsen is currently in a Phase II/III clinical trial, known as the ILLUMINATE trial, targeting Leber Congenital Amaurosis 10 (LCA10). Ultevursen is also undergoing Phase II/III evaluation for the treatment of USH2A-mediated retinitis pigmentosa and Usher syndrome. Beyond its clinical programs, ProQR is actively developing its proprietary Axiomer RNA base-editing platform technology. Strategic collaborations are central to ProQR's strategy, evidenced by its licensing agreements with institutions such as Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center. Furthermore, a significant license and research partnership exists with Eli Lilly and Company, focused on the discovery, advancement, and commercialization of novel medicines for genetic conditions impacting the liver and nervous system. Established in 2012, ProQR Therapeutics N.V. maintains its corporate headquarters in Leiden, the Netherlands.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Weak
56/100

Analyst Price Target

ⓘ
Average Target
$846.67
▼ −2.0% Downside
High Target$953.12
Low Target$647.29
Based on 27 analysts

Latest News & Updates

🚀
CNBC·2h ago

PROQR THERAPEUTICS NV tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
MarketWatch·5h ago

Analysts lift PRQR price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Barron’s·1d ago

PROQR THERAPEUTICS NV announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.